drugset / Trial / NCT02995707

The Effective and Safety of Thalidomide in NTDT

NCT02995707 ↗

Phase 2 Unknown 30 enrolled Xiao-Lin Yin
NaSingle-groupOpen-labelTreatment

Summary

This is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of NTDT to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the adverse reactions caused by transfusion.15\~30 patients will be enrolled, including type α 5\~13 cases, type β 10\~17 cases.

Timeline

Start
2016-09
Primary completion
2017-12
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 50 mg Oral

Indications